Glucokinase plays an important role in regulating the blood glucose level and serves as an essential therapeutic target in type 2 diabetes management. Entada africana is a medicinal plant and highly rich source of bioactive ligands with the potency to develop new target drugs for glucokinase such as diabetes and obesity. Therefore, the study explored a computational approach to predict identified compounds from Entada africana following its intermolecular interactions with the allosteric binding site of the enzymes. We retrieved the three-dimensional (3D) crystal structure of glucokinase (PDB ID: 4L3Q) from the online protein data bank and prepared it using the Maestro 13.5, Schrödinger Suite 2022-3. The compounds identified were subjected to ADME, docking analysis, pharmacophore modeling, and molecular simulation. The results show the binding potential of the identified ligands to the amino acid residues, thereby suggesting an interaction of the amino acids with the ligand at the binding site of the glucokinase activator through conventional chemical bonds such as hydrogen bonds and hydrophobic interactions. The compatibility of the molecules was highly observed when compared with the standard ligand, thereby leading to structural and functional changes. Therefore, the bioactive components from Entada africana could be a good driver of glucokinase, thereby paving the way for the discovery of therapeutic drugs for the treatment of diabetes and its related complications.
Poly (ADP‐ribose) polymerase 1 is a versatile enzyme that is deeply involved in diverse cellular processes. It exerts influence on pivotal activities such as DNA repair, transcriptional regulation, and cell death. PARP1 is crucial due to its susceptibility to posttranslational modifications, each of which has distinct roles in shaping its functionality and interactions with other proteins. Among these modifications, the addition of ADP‐ribose polymerase 1 and the addition of an acetyl group to lysine residues enhance PARP1 engagement in DNA repair, while ubiquitination and cleavage are involved in the degradation of PARP1. PARP1 modification has been exploited in cancer treatment, particularly in the context of breast and ovarian cancers marked by BRCA1 and BRCA2 mutations. However, resistance to PARP1 inhibitors and selective posttranslational modifications, which confer cellular functions remain elusive. The present review endeavors to detail the extent of PARP1 modifications, shedding light on their profound implications at the cellular remains a challenge, which often drives treatment failure. The effectiveness of PARP1 inhibitors relies on specific level. This trial is registered with NCT04550104, NCT06120491, NCT05367440, NCT05797168, NCT04644068, NCT05573724, NCT05489211, NCT05938270, and NCT02264678.
Resistance to treatment remains a significant challenge in the management of lung cancer. The mechanisms underlying resistance include gene mutation, tumor heterogeneity, and immune evasion. Dysregulation of functional genes and miRNAs is a consistent feature of tumors displaying drug resistance. In this study, we aimed to characterize and identify dysregulated miRNAs and their role in gefitinib-resistant lung cancer. The gefitinib-resistant lung cancer cell line A549GFR was generated and subjected to small RNA sequencing to identify dysregulated microRNAs. We identified miR-493-3p as one of the significantly downregulated miRNAs. DPY30 was identified as a potential target of miR-493-3p To further investigate this phenomenon, we employed qPCR, Western blot, flow cytometry, immunohistochemistry, flow cytometry and apoptosis assays for different biological parameters. The results revealed that DPY30, which is critical for regulating cell cycle progression and maintaining stemness, was upregulated in both the A549GFR and the EGFR-mutant H1975GFR cell lines. We confirmed that DPY30 is indeed a target of miR-493-3p Further analysis revealed that downregulation of DPY30 reversed the resistance characteristics of both cell lines, including reversion of stemness and inhibition of cell cycle progression. Upregulation of miR-493-3p suppressed DPY30 expression, leading to similar effects. These in vitro results were also observed in vivo when gefitinib-resistant tumor xenografts were established in nude mice. This research highlights the role of miR-493-3p in lung cancer gefitinib-responsive mechanisms by targeting the DPY30-mediated resistance pathway. Therefore, the miR-493-3p/DPY30 axis could be a promising target for sensitizing lung cancer to gefitinib.